Foard Brian 4

What Happened

• Brian Foard, Executive Vice President, Specialty, Pharma & ID at Merck (MRK), was granted three derivative awards on 2026-05-05 totaling 77,000 units (10,605 + 35,351 + 31,044). Each grant is reported at $0.00 (award/derivative), meaning no cash purchase was reported in the Form 4; the filing does not state a dollar value for the awards.

Key Details

• Transaction date: 2026-05-05; Form 4 filed: 2026-05-07 (within the typical 2-business-day filing window).
• Reported amounts: 10,605 RSUs; 35,351 RSUs; 31,044 RSUs — total 77,000 units.
• Price reported: $0.00 (derivative awards — not an open-market purchase).
• Shares owned after the transaction: not specified in the provided filing data.
• Footnotes: F1—each restricted stock unit is a contingent right to one share; F2—these RSUs vest and are distributed in three equal installments on 5/5/2027, 5/5/2028, and 5/5/2029; F3—one award/option (as noted) vests on the same schedule.
• Filing timeliness: filed two days after the transaction date; no late filing flag indicated.

Context

• These are award/derivative grants (RSUs and an award/option referenced in the footnotes), not open-market purchases or sales. RSUs give a contingent right to receive shares upon vesting; economic value depends on Merck’s share price at distribution and any applicable tax withholdings. Such grants are common part of executive compensation and do not by themselves indicate a buy/sell signal.